A major international review has found that commercially legalised cannabis markets — such as those in the United States and Canada — are associated with increased usage, higher-potency products, and more hospital admissions for psychosis and other mental health disorders. By contrast, countries that have simply decriminalised possession, or legalised cannabis under strict state control as Uruguay did in 2013, showed little evidence of rising use or psychiatric illness. Published in the journal Lancet Psychiatry, the findings suggest that it is the for-profit model of cannabis sales, not legalisation itself, that drives harm — with researchers warning that a commercially incentivised industry, much like tobacco and alcohol before it, has strong financial motives to push cheaper, more potent products to as many consumers as possible.